drugset
drugset / Trial / NCT04470726

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

NCT04470726 ↗

Phase 1/2 Completed 26 enrolled AiViva BioPharma, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.

Timeline

Start
2020-08-18
Primary completion
2023-06-20
Completion
2023-07-28

Drugs

EvaluationDrugModalityDoseRoute
Subject AIV001 Unknown — Other

Indications

nodular basal cell carcinoma